PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29303722
OWN - NLM
STAT- MEDLINE
DCOM- 20180110
LR  - 20180111
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 390
IP  - 10114
DP  - 2018 Dec 23
TI  - Concerns about cardiotoxicity in the HERA trial - Authors' reply.
PG  - 2767-2768
LID - S0140-6736(17)31940-2 [pii]
LID - 10.1016/S0140-6736(17)31940-2 [doi]
FAU - Cameron, David A
AU  - Cameron DA
AD  - Edinburgh Cancer Centre, Western General Hospital, Edinburgh EH4 2XU, UK.
      Electronic address: [email protected]
FAU - Gelber, Richard D
AU  - Gelber RD
AD  - Edinburgh Cancer Centre, Western General Hospital, Edinburgh EH4 2XU, UK.
FAU - Procter, Marion
AU  - Procter M
AD  - Edinburgh Cancer Centre, Western General Hospital, Edinburgh EH4 2XU, UK.
FAU - Suter, Thomas
AU  - Suter T
AD  - Edinburgh Cancer Centre, Western General Hospital, Edinburgh EH4 2XU, UK.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Antineoplastic Agents)
RN  - P188ANX8CK (Trastuzumab)
SB  - AIM
SB  - IM
CON - Lancet. 2018 Dec 23;390(10114):2767. PMID: 29303721
CON - Lancet. 2017 Mar 25;389(10075):1195-1205. PMID: 28215665
MH  - Antineoplastic Agents/adverse effects
MH  - Breast Neoplasms/*drug therapy
MH  - *Cardiotoxicity
MH  - Humans
MH  - Trastuzumab/adverse effects
EDAT- 2018/01/06 06:00
MHDA- 2018/01/11 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/07/04 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/11 06:00 [medline]
AID - S0140-6736(17)31940-2 [pii]
AID - 10.1016/S0140-6736(17)31940-2 [doi]
PST - ppublish
SO  - Lancet. 2018 Dec 23;390(10114):2767-2768. doi: 10.1016/S0140-6736(17)31940-2.